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  Neocarzinostatin was administrated to 9 patients with transitional cell cancer originated from
the urinary bladder or the renal pelvis， and 6 patlents with adenocarcinoma from the prostate． All
patients had objective and measurable metastatic lesions such as 8 with palpable mass， 9 with bone
metastasis demonstrable by bone scintigram， and S with pulmonary metastasis demonstrable by chest
X－ray．
  Neocarzinostatin was administrated intravenously daily or twice a． week with ．dos4ge ranging
from 1 mg or 2 mg， and with total dosages ranging from 6 mg to 50 mg．
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  Side effect was seen in 9 patients of digestive complaints， and 5 of thrombocytopenia．
  Neocarzinostatin demonstrated therapeutic effect in 2 patients （Kalnofsky： 1－C）． Our results
reveal the eficacy of Neocarzinostatin to advanced urogenital can¢er．






































治 療 成 績
治療効果はKarnofskyの基準によると，0－012
Tab工e 1． Patients treated with neocarzinostatin
Case   Sex Age Diagnosis
No．
Pr mary treatmentChemotherapy beforeadministration of NCS





































45 Renal pelvic ca．





































Lung，liver ＆ iymphnode mata，
Local recurrence
Bone meta Lecal recurrence．
Lung，bone ＆ iymphnode meta．
Lung ＆ bone meta．
Locai recurrence
Liver ＆ lung meta．
Local recurrence
Bone ＆ lymphnode meta．
LocaS recurr即ce
Bone ＆ lymphnode meta．
Bone meta Local recurrence．
Bone meta．
Primary seat





































Table 2． Dosage and effect of neocarzinostatin
Cace
No，





































































































Table 3． Change of numerical value on blood and serum examination （before dosage of NCS）
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Table 4． Change of numeri6al value on blood and serum examination （after dosage of NCS）
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